| Status: Excluded due to NICE appraisal | |
Product meets AWMSG exclusion criteria due to NICE appraisal TA518: Tocilizumab for treating giant cell arteritis |
|
Medicine details |
|
| Medicine name | tocilizumab (RoActemra®) |
| Formulation | 162 mg solution for injection |
| Reference number | 2219 |
| Indication | Treatment of giant cell arteritis in adult patients |
| Company | Roche Products Ltd |
| BNF chapter | Musculoskeletal & joint diseases |
| Assessment type | N/A |
| Status | Excluded due to NICE appraisal |
| Date of issue | 02/08/2017 |
| NICE guidance | |